HR & Management

Published

Glide Pharma in the money

1 Mins

Glide, which was established in 2001, has developed a solid dose delivery system for a range of drug and vaccine applications.

The company aims to offer an alternative to the traditional needle injection currently used in many forms of vaccination.

The device is operated by a spring mechanism which pushes solid drugs through the skin and into the underlying tissue, where they dissolve and are released into the patient’s bloodstream.

Drugs in a solid dose form also make them more stable, removing the need for refrigeration and offering the potential to generate substantial cost savings.

Oxford Technology 4 VCT, Oxford Capital Partners and a number of business angels previously provided the company with a £2.3m third round of funding in 2007.

“This funding reflects the major progress we have made in positioning the Glide SDI system as a mainstream alternative for the injection of small molecules, biopharmaceuticals and vaccines,” says Glide Pharma founder Charles Potter.

Picture source

Share this story

More government contracts must go to SMEs
First Alan Sugar, now Philip Green
Send this to a friend